HUTCHMED (China) Limited (NASDAQ:HCM) to Post FY2025 Earnings of $0.05 Per Share, Trinity Delta Forecasts

HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) - Equities researchers at Trinity Delta issued their FY2025 earnings per share (EPS) estimates for HUTCHMED in a note issued to investors on Wednesday, April 3rd. Trinity Delta analyst L. Gregorek anticipates that the company will earn $0.05 per share for the year. The consensus estimate for HUTCHMED's current full-year earnings is ($0.48) per share.

A number of other research analysts have also weighed in on HCM. Cantor Fitzgerald restated an "overweight" rating on shares of HUTCHMED in a report on Friday, January 12th. StockNews.com raised HUTCHMED from a "hold" rating to a "buy" rating in a research report on Wednesday, March 27th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $29.70.

HUTCHMED Trading Down 3.0 %

Shares of HCM stock traded down $0.51 during trading hours on Friday, reaching $16.36. The company had a trading volume of 51,431 shares, compared to its average volume of 119,550. HUTCHMED has a 12 month low of $10.68 and a 12 month high of $20.73. The company has a quick ratio of 2.60, a current ratio of 2.72 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $15.26 and a 200-day simple moving average of $16.68.

Institutional Trading of HUTCHMED

A number of large investors have recently bought and sold shares of HCM. Goldman Sachs Group Inc. grew its position in shares of HUTCHMED by 15.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 475,370 shares of the company's stock valued at $8,609,000 after purchasing an additional 62,762 shares in the last quarter. FIL Ltd grew its position in shares of HUTCHMED by 6.2% in the fourth quarter. FIL Ltd now owns 75,993 shares of the company's stock valued at $1,376,000 after purchasing an additional 4,452 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of HUTCHMED in the fourth quarter valued at $406,000. Sei Investments Co. purchased a new position in shares of HUTCHMED in the fourth quarter valued at $197,000. Finally, Envestnet Asset Management Inc. purchased a new position in shares of HUTCHMED in the fourth quarter valued at $274,000. 8.82% of the stock is owned by hedge funds and other institutional investors.

About HUTCHMED

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.